NANO MRNA Co.,Ltd. (FRA:3NQ)

Germany flag Germany · Delayed Price · Currency is EUR
0.800
0.00 (0.00%)
At close: Dec 5, 2025
-13.51%
Market Cap 58.93M
Revenue (ttm) 817.81K
Net Income (ttm) -4.36M
Shares Out n/a
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.800
Previous Close 0.800
Day's Range 0.800 - 0.800
52-Week Range 0.660 - 1.150
Beta n/a
RSI 52.39
Earnings Date Feb 13, 2026

About NANO MRNA

NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1996
Employees 20
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3NQ
Full Company Profile

Financial Performance

In 2024, NANO MRNA's revenue was 108.00 million, a decrease of -20.00% compared to the previous year's 135.00 million. Losses were -835.00 million, 7.05% more than in 2023.

Financial numbers in JPY Financial Statements

News

There is no news available yet.